Allergan Plc is no longer looking at selling its women’s health business, Chief Executive Officer Brent Saunders said on Tuesday.
“For Women’s Health, we have concluded that the highest value proposition for this business at this time is to continue managing it and optimizing it,” Saunders said.
Saunders also said the company’s anti-infectives business will “more likely than not” be sold over the near term.
The company had said in May it was looking to sell both its women’s health and infectious disease units following a review of its businesses.
By Tamara Mathias
The Serum Institute of India (SII) expects to soon receive World Health Organisation (WHO) emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, produced for mid and low-income countries.
According to the deal, Sanofi will gain full global rights to Kymab’s fully human monoclonal antibody, KY1005 that attaches to OX40-Ligand and can potentially treat various immune-mediated diseases and inflammatory ailments.
Moderna tapped veteran Amgen executive Corinne Le Goff to spearhead that effort as chief commercial officer.